Literature DB >> 24093684

Purified hepatitis B virus induces human mesangial cell proliferation and extracellular matrix expression in vitro.

Zongli Diao1, Jiaxiang Ding, Chenghong Yin, Liyan Wang, Wenhu Liu.   

Abstract

BACKGROUND: Hepatitis B virus (HBV) induces proliferation of human mesangial cells (HMCs), and extracellular matrix expression through the deposition of immune complexes in renal tissue. However, it is unclear whether HBV can directly affect HMCs. In this study, the effects of purified HBV on HMC proliferation and extracellular matrix expression in vitro was determined.
FINDINGS: HBV was purified using sucrose density gradient centrifugation. HMCs were co-cultured with purified HBV (104-106 copies/ml) for 48 h, and cell proliferation determined using 5-ethynyl-2'-deoxyuridine immunofluorescence assays. After HMCs were co-cultured with 106 copies/ml purified HBV for 0, 12, 24, 36 and 48 h, expression of type IV collagen and fibronectin was measured using enzyme-linked immunosorbent assays. Three titers of purified HBV (10(4), 10(5), and 10(6) copies/ml) induced HMC proliferation, with the proportion of increases in cell numbers at 24.7 ± 4.3, 31.2 ± 9.4, and 36.8 ± 7.5%, respectively. All these increases were significantly higher than those for the control group (13.6 ± 4.2%) (All p < 0.05). Purified HBV (10(6) copies/ml) significantly increased the levels of type IV collagen and fibronectin in supernatants compared with the control group at 12 and 48 h (All p < 0.05).
CONCLUSIONS: Purified HBV can directly promote HMC proliferation and expression of type IV collagen and fibronectin, and could be involved in the pathogenesis of HBV-associated glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24093684      PMCID: PMC3852991          DOI: 10.1186/1743-422X-10-300

Source DB:  PubMed          Journal:  Virol J        ISSN: 1743-422X            Impact factor:   4.099


Introduction

Hepatitis B virus (HBV) infections are prevalent in China [1], and infection with this virus can result in the development of HBV-associated glomerulonephritis (HBV-GN). HBV-GN has become a prevalent type of secondary glomerulonephritis in China [2]. Human mesangial cell (HMC) proliferation and increases in the expression of extracellular matrix proteins, including type IV collagen and fibronectin (FN), were involved in various pathological types of HBV-GN. The most common pathological type of HBV-GN is HBV-associated membranous nephropathy (HBV-MN). Proliferation of HMCs, and increases in extracellular matrix protein levels are more common in HBV-MN compared with the idiopathic form [3]. Additionally, HMC proliferation and increases in extracellular matrix protein expression are common in other pathological types of HBV-GN such as membranoproliferative glomerulonephritis. The most widely accepted mechanism for increases in HMC proliferation, and expression levels of extracellular matrix proteins in HBV-GN is through the deposition of HBV immune complexes [4]. Many studies have shown that expression of HBV DNA in glomeruli suggests direct viral-induced pathological alterations of HMC could contribute to the pathogenesis of HBV-GN [5,6]. The main effect of HBV DNA in renal tissues on HMCs was because of HBV antigens (HBAg) and HBV antibodies (HBAb) forming immune complexes in situ[5,7]. It remains unclear whether HBV can directly affect HMCs; therefore, in this study we purified HBV virons and subviral particles from the serum of HBV-infected patients, and investigated the effects of purified HBV on HMC proliferation, and on the expression levels of type IV collagen and FN.

Methods

Isolation and purification of HBV

We isolated HBV from the HBV DNA-positive sera of chronic HBV patients, in our hospital, containing more than 5.0 × 108 copies/ml of circulating HBV. Virus was purified by sucrose density gradient centrifugation as previously described [8].

Cell culture and cell proliferation assays

HMCs (ScienCell, San Diego, CA, USA) were cultured in Mesangial Cell Medium (MsCM; ScienCell, Carlsbad, USA) at 37°C/5% CO2. Cells were seeded into 12-well culture plates at a density of 1.0 × 104 cells/well and incubated for 24 h in RPMI 1640 medium. We then applied HBV at various doses (104, 105, and 106 copies/ml) to HMC cultures. At 48 h post-seeding, cell proliferation was determined using 5-ethynyl-2′-deoxyuridine (EdU) immunofluorescence assays according to the manufacturer’s instructions (Ribobio, Guangzhou, Guangdong, China). The culture medium was replaced with normal MsCM containing 50 μM EdU. After a 3-h incubation, cells were fixed with formaldehyde. After washing with phosphate-buffered saline (PBS) containing 0.5% Triton X-100, cells were washed with PBS and counterstained with Hoechst 33342. Cells were visualized by fluorescence microscopy and using Image-Pro Plus 6.0 (Media Cybernetics, Rockville, MD, USA). The level of HMC proliferation was determined using the following formula:

Enzyme-linked immunosorbent assays (ELISAs)

Cells were seeded into 12-well culture plates at a density of 1.0 × 104 cells/well and incubated for 24 h in normal RPMI 1640 medium. We then applied MsCM alone, or 106 copies/ml of HBV in MsCM. At 0, 12, 24, 36, and 48 h post-seeding, the supernatants of each well were collected, and type IV collagen and FN levels measured by ELISA according to the manufacturer’s instructions (Blue-gene, Shanghai, China).

Statistical analysis

All data were expressed as the mean ± the standard error of the mean (SEM). Statistical analysis was carried out using Tamhane’s T2 test for HMC proliferation, and the Independent-Samples T-test for type IV collagen and FN. Differences were considered significant when the P-value was less than 0.05. All results were repeated for three times.

Results

HMC Proliferation

Proliferation of HMCs in control, 104, 105, and 106 copies/ml HBV-infected cultures were increased by 13.6 ± 4.1, 24.7 ± 4.3, 31.2 ± 9.4, and 36.8 ± 7.5%, respectively (Figure 1).
Figure 1

Various titers of HBV can induce HMC proliferation after 48 h. (A) Detection of EdU (left) and Hoechst3342 (center) incorporation in cultured HMCs, and overlay images (right). (B) HMC proliferation in control and HBV co-culture groups. **p < 0.05 compared with that in normal MsCM. **p < 0.05 compared with that in MsCM containing 104 copies/ml HBV. Results are presented as means ± SEM.

Various titers of HBV can induce HMC proliferation after 48 h. (A) Detection of EdU (left) and Hoechst3342 (center) incorporation in cultured HMCs, and overlay images (right). (B) HMC proliferation in control and HBV co-culture groups. **p < 0.05 compared with that in normal MsCM. **p < 0.05 compared with that in MsCM containing 104 copies/ml HBV. Results are presented as means ± SEM.

Extracellular matrix protein levels

Using 106 copies/ml HBV significantly increased the expression levels of type IV collagen and FN in HMCs (p < 0.05; Figure 2).
Figure 2

HMCs were co-cultured with purified HBV. Type IV collagen (A) and FN (B) levels in supernatants increased significantly compared with controls at 12, 24, 36, and 48 h (p < 0.05).

HMCs were co-cultured with purified HBV. Type IV collagen (A) and FN (B) levels in supernatants increased significantly compared with controls at 12, 24, 36, and 48 h (p < 0.05).

Discussion

In our study, we found that purified HBV significantly increased HMC proliferation, and also increased expression levels of type IV collagen and FN. The major mechanism of increased HMC proliferation and extracellular matrix expression in HBV-GN is suggested to be due to HBV immune complex deposition [6,9]. However, many studies have detected HBV DNA, as both free and integrated forms, in mesangial cells. He et al. have reported that the expression of HBV DNA in the nucleus and cytoplasm of HMCs in HBV-GN patients verified the presence of HBV DNA in HMC [5]. Wang et al. showed that HBV DNA as the integrated form was detected in 82% (41/50) of cases in HMCs by in situ hybridization [7]. These observations suggest that HBV DNA can infect HMCs, and that it can directly induce pathological alterations in HMCs that might be involved in HBV-GN [10]. However, these studies were all conducted in renal tissues, and the effects of HBV on HMCs were suggested to be a result of immune complex formation in situ[7,11]. Because of confounding factors involving immune complexes that are circulating, it was difficult to show whether HBV can directly affect HMCs in these studies. In our study, we purified HBV from the sera of HBV-infected patients. The HMCs were co-cultured with purified HBV in vitro, thereby overcoming the confounding factors related to the immune complex, and we showed that purified HBV directly affected HMCs. There were some limitations to our study. We did not explore the mechanisms through which HBV increased HMC proliferation and expression of extracellular matrix proteins. HBV X Protein (HBx) acts an indirect transcriptional transactivitor to regulate cell proliferation, transdifferentiation and apoptosis [12]. Some studies have shown that HBx can induce mesangial cell proliferation through the upregulation of interleukin-1β and interleukin-6 [13]. However, in these previous studies, HBx was transfected into mesangial cells artificially; therefore, it remains unknown whether HBV can induce HMC proliferation through a natural infection. Further studies will be required to clarify this. In conclusion, our findings support the hypothesis that HBV exerts direct effects on HMCs, and will hopefully enrich our understanding of the pathogenesis of HBV-GN.

Abbreviations

EdU: 5-ethynyl-2′-deoxyuridine; ELISA: Enzyme-linked immunosorbent assay; FN: Fibronectin; HBV: Hepatitis B virus; HBV-GN: HBV-associated glomerulonephritis; HBV-MN: HBV-associated membranous nephropathy; HBx: HBV X protein; HMC: Human mesangial cells; MsCM: Mesangial cell medium.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

DZ and JD carried out all experiments in this study, collated the information, performed the literature search and drafted the manuscript. CY performed the EdU assays. LW performed the ELISA experiments. WL, the corresponding author, designed the research project, performed the literature search and prepared the manuscript. All authors read and approved the final manuscript.
  13 in total

Review 1.  Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy.

Authors:  Y Takekoshi; H Tochimaru; Y Nagata; N Itami
Journal:  Kidney Int Suppl       Date:  1991-12       Impact factor: 10.545

2.  In situ hybridization of hepatitis B DNA in hepatitis B-associated glomerulonephritis.

Authors:  X Y He; L J Fang; Y E Zhang; F Y Sheng; X R Zhang; M Y Guo
Journal:  Pediatr Nephrol       Date:  1998-02       Impact factor: 3.714

3.  Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes.

Authors:  Dieter Glebe; Stephan Urban; Eva V Knoop; Nilgün Cag; Peter Krass; Stefanie Grün; Aiste Bulavaite; Kestutis Sasnauskas; Wolfram H Gerlich
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

4.  Immune-complex glomerulonephritis--deposits plus interest.

Authors:  G B Appel
Journal:  N Engl J Med       Date:  1993-02-18       Impact factor: 91.245

5.  Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy.

Authors:  Ping Li; Ri-Bao Wei; Li Tang; Jie Wu; Xue-Guang Zhang; Xiang-Mei Chen
Journal:  Clin Nephrol       Date:  2012-12       Impact factor: 0.975

6.  Detection of hepatitis B virus DNA and RNA in kidneys of HBV related glomerulonephritis.

Authors:  K N Lai; R T Ho; J S Tam; F M Lai
Journal:  Kidney Int       Date:  1996-12       Impact factor: 10.612

7.  Role of hepatitis B virus infection in pathogenesis of IgA nephropathy.

Authors:  Nian-Song Wang; Zhao-Long Wu; Yue-E Zhang; Mu-Yi Guo; Lv-Tan Liao
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

8.  Replication and infectivity of hepatitis B virus in HBV-related glomerulonephritis.

Authors:  Lizhang Chen; Chengqiu Wu; Xuegong Fan; Jianming Gao; Hongling Yin; Tom Wang; Jun Wu; Shi Wu Wen
Journal:  Int J Infect Dis       Date:  2008-11-25       Impact factor: 3.623

9.  The effect of hepatitis B vaccination on the incidence of childhood HBV-associated nephritis.

Authors:  Hong Xu; Li Sun; Li-Jun Zhou; Li-Jun Fang; Fang-Yun Sheng; Yi-Qing Guo
Journal:  Pediatr Nephrol       Date:  2003-10-30       Impact factor: 3.714

10.  HBV X gene transfection upregulates IL-1beta and IL-6 gene expression and induces rat glomerular mesangial cell proliferation.

Authors:  Hongzhu Lu; Jianhua Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-06-19
View more
  5 in total

1.  MicroRNA-223 downregulation promotes HBx-induced podocyte pyroptosis by targeting the NLRP3 inflammasome.

Authors:  Yani Yu; Hui Dong; Yue Zhang; Jingyi Sun; Baoshuang Li; Yueqi Chen; Moxuan Feng; Xiaoqian Yang; Shengbo Gao; Wei Jiang
Journal:  Arch Virol       Date:  2022-06-22       Impact factor: 2.685

2.  Hepatitis B virus X mediates podocyte pyroptosis by regulating the ROS/NLRP3 signaling pathway in hepatitis B virus-associated glomerulonephritis.

Authors:  Yani Yu; Hui Dong; Jingyi Sun; Baoshuang Li; Yueqi Chen; Moxuan Feng; Xiaoqian Yang; Wei Jiang
Journal:  Iran J Basic Med Sci       Date:  2022-01       Impact factor: 2.532

3.  Chronic hepatitis B virus infection increases the risk of upper urinary calculi.

Authors:  Bingbing Hou; Changming Lin; Zongyao Hao
Journal:  BMC Urol       Date:  2022-06-06       Impact factor: 2.090

4.  Clinicopathological characteristics and prognosis of hepatitis B associated membranous nephropathy and idiopathic membranous nephropathy complicated with hepatitis B virus infection.

Authors:  Ruiqiang Wang; Yunqi Wu; Bowen Zheng; Xiaofeng Zhang; Dongyue An; Ningning Guo; Jin Wang; Yuanyuan Guo; Lin Tang
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

5.  Hepatitis B Virus-Related Glomerulonephritis with Positive and Negative Serum HBsAg: Different Clinicopathologic Characteristics of Two Clinical Subtypes.

Authors:  Feng Yu; Guanglan Li; Wenke Hao; Wenxue Hu
Journal:  Int J Gen Med       Date:  2021-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.